In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Precision BioSciences (DTIL – Research Report), with a price target of $30.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Soumit Roy’s rating is based on Precision BioSciences’ strategic focus on developing their ARCUS gene editing platform, particularly with the PBGENE-DMD asset, which shows promise as a potential best-in-class treatment for Duchenne muscular dystrophy (DMD). The company plans to complete preclinical studies and file for regulatory approval by 2025, with initial clinical data expected in 2026. The positive preclinical results in humanized mouse models suggest a strong potential for success, addressing up to 60% of DMD cases, which is significantly higher than existing treatments.
Additionally, Precision BioSciences is progressing with their PBGENE-HBV program in chronic hepatitis B, although updates on this trial are expected later. The company’s decision to pause the PBGENE-3243 program reflects a strategic allocation of resources to prioritize their most promising assets. Overall, the combination of promising preclinical data, strategic focus on high-potential programs, and a clear development timeline supports the Buy rating.
According to TipRanks, Roy is an analyst with an average return of -28.5% and a 16.97% success rate. Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Elicio Therapeutics, and Chimerix.
In another report released yesterday, BMO Capital also reiterated a Buy rating on the stock with a $13.00 price target.